Alpha-MSH and the Derivation of KPV
KPV denotes lysine–proline–valine, a three-residue sequence discussed as the C-terminal portion of alpha-MSH. The sequence relationship explains the research lineage. It does not establish that isolated KPV reproduces the full peptide's receptor behaviour.
Define the entity before following the lineage
The ChEBI KPV reference record describes a particular free-carboxylic-acid entity. When reading an experiment, check the actual terminal chemistry and preparation rather than assuming every use of “KPV” describes that exact form. [3]
Transport and signalling are different questions
Dalmasso and colleagues examined PepT1-mediated uptake and inflammatory responses in cell systems and mouse colitis models. Uptake through a peptide transporter is a different mechanistic question from direct agonism at a melanocortin receptor. [1]
Kannengiesser and colleagues studied KPV in two mouse-colitis models, including mice with nonfunctional MC1R. Their findings supported at least partial independence from that receptor in the tested context. They did not establish independence from every receptor or pathway in all settings. [2]
Keep the inference proportional to the experiment
| Observation | Appropriate interpretation |
|---|---|
| A sequence occurs within a larger peptide | A structural relationship is present |
| A transporter contributes to uptake | That transport process matters in the tested system |
| A response remains in a receptor-deficient model | The response is not wholly dependent on that receptor under those conditions |
| A published effect uses a formulated preparation | The formulation belongs to the evidence, alongside the peptide |
These distinctions help avoid treating a derivation diagram as a complete mechanism. They also prevent a cell or mouse finding becoming a claim about personal use.
The KPV profile covers molecular specification; receptor selectivity explains the pharmacology terms. For procurement, compare the exact entity and available lot evidence rather than relying on a familiar parent-peptide name.
Explore the related evidence
| Resource | Why open it |
|---|---|
| KPV and BPC-157 Compared | Distinguish KPV and BPC-157 by peptide identity and analytical requirements rather than comparing promised outcomes. |
| KPV 10 mg | Open the product record for its nominal presentation and current purchasing information. |
| Compound Index | Find another molecular profile without confusing it with a vial. |
| Guides & Resources | Choose another scientific, analytical or procurement guide. |
Sources and scope
- Dalmasso et al. (2008). PepT1-mediated KPV uptake and inflammatory responses. Gastroenterology.Human cell lines including Jurkat T cells; PepT1 uptake; DSS/TNBS mouse models. Full-text access attempt returned an error/challenge; no full-text claim. Access: Original article abstract retrieved through official Europe PMC core record
- Kannengiesser et al. (2008). KPV in two mouse-colitis models. Inflammatory Bowel Diseases.DSS and transfer colitis; nonfunctional MC1R supports at-least-partial independence, not universal receptor independence. Access: Original article abstract retrieved through official Europe PMC core record
- ChEBI. Lys-Pro-Val, CHEBI:160254.Free-carboxylic-acid reference identity. Not a lot measurement or proof of terminal chemistry in published preparations. Access: Opened official ChEBI record